VivoSim Labs

Yahoo Finance • 10 days ago

Tuesday's session: top gainers and losers

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT GORV [https://www.chartmill.com/stock/quote/GORV/profile] 147.0% Wi... Full story

Yahoo Finance • 16 days ago

NIO Inc. Announces Pricing of US$1 Billion Equity Offering

SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced the pricing of its US$1 billion... Full story

Yahoo Finance • 23 days ago

On Wednesday, there are stocks with unusual volume. Let's take a look.

Which stocks have an unusual volume on Wednesday? [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PSNYW [https://www.chartmill.com/stock/quote/PSNYW/profile] 25.04% POLESTAR AUTO CLASS C-1 ADS (NASDAQ:PSNY... Full story

Yahoo Finance • 23 days ago

Which stocks are experiencing notable movement on Wednesday?

Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT AIHS [https://www.c... Full story

Yahoo Finance • 24 days ago

Unusual volume stocks in Tuesday's session

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT SOGP [https://www.chartmill.com/stock/quote/SOGP/profi... Full story

Yahoo Finance • 24 days ago

NIO, XPeng, Li Auto Log Strong August Deliveries Highlighting China's EV Momentum

Chinese electric vehicle makers reported strong delivery gains in August 2025, underscoring their push to scale production, expand infrastructure, and accelerate new technology rollouts as they vie for dominance in the world’s largest EV m... Full story

Yahoo Finance • last month

Vivos CEO Korenko buys $7,660 in shares

Vivos Inc (EXCHANGE:RDGL) CEO and President Michael K. Korenko, according to a Form 4 filing, has purchased 100,000 shares of common stock on August 14, 2025. The shares were bought at a price of $0.0766, for a total transaction value of $... Full story

Yahoo Finance • last month

VivoSim Labs names Tony Lialin as chief commercial officer

SAN DIEGO - Pharmaceutical and biotechnology services company VivoSim Labs, Inc. (NASDAQ:VIVS), currently valued at $4.84 million and considered undervalued according to InvestingPro Fair Value metrics, has appointed Tony Lialin as its Chi... Full story

Yahoo Finance • last month

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in th... Full story

Yahoo Finance • 2 months ago

Nio Inc. (NIO) umbles 8% as Slow July Deliveries Growth Disappoint

We recently published 10 Stocks Bleeding Early. NIO Inc. (NYSE:NIO) is one of the companies that stood stronger last week. Nio Inc. dropped its share prices by 8.18 percent on Monday to close at $4.6 apiece as investors soured on the slow... Full story

Yahoo Finance • 4 months ago

VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinc... Full story

Yahoo Finance • 5 months ago

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies,... Full story